Type 1 DiabetesACTNCT02526069
An ACT Based Application for Young People With Type 1 Diabetes
A study testing Acceptance and Commitment Therapy in people with Type 1 Diabetes, run by University of Edinburgh at 1 site in United Kingdom.
Trial summary
Study Objectives: This study aims to assess the feasibility and acceptability of an application utilising Acceptance and Commitment Therapy in young people with type 1 diabetes. Primary Research Questions: Is an ACT based application feasible and acceptable to young people with type 1 diabetes. Read more about this study
- Who is it for?
- Ages 13 to 22 yearsHealthy volunteers can take part
- Conditions the study is for
- Type 1 Diabetes
- What is being tested?
- Acceptance and Commitment Therapy
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 17 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- May 2015to Apr 2016
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 13 to 22 years
- All sexes
- Healthy volunteers accepted
- Child, Adult
Who may be able to join
- 13-22 year olds diagnosed with type 1 diabetes or a clinician working in this field
- Understand English
- Android phone
- If a patient to have been diagnosed for at least 6 months
- Ability to give consent
Who cannot join
- Young people experiencing significant mental health issues. This includes those who are suicidal, experiencing psychosis, or are severely depressed. This will be assessed by the diabetes team which includes psychologists and those potential participants which meet this exclusion criteria will not be asked to participate in the study by the diabetes or research team.
Trial locations and contacts
1 site in 1 country.
About this study
Study Objectives:
This study aims to assess the feasibility and acceptability of an application utilising Acceptance and Commitment Therapy in young people with type 1 diabetes.
Read more
Primary Research Questions:
Is an ACT based application feasible and acceptable to young people with type 1 diabetes.
Study Design:
Patients will use the app for four weeks and then be invited to attend an interview discussing the acceptability, usability and feasibility of the app. Clinician's will also be invited to take part in a workshop where they interact with the app and provide feedback.
Consent for will be obtained through the app. Additional consent for the recording of interviews will be obtained in paper format and stored in a secure locked cabinet at Edinburgh University.
Quantitative data will also be collected on well-being, psychological flexibility, and data usage.
Data Collection
Qualitative feedback:
Interviews will be recorded and transcribed using unique identifiers.
Outcome measures and data usage patterns:
Data will be collected on a password protected database which can only be obtained via a password protected and encrypted server from University of Edinburgh.
Data Analysis:
Phase 1:
Framework analysis and interpretive phenomenological analysis will be utilised to create themes from the qualitative feedback.
Read the detailed description
Study Design:
The diabetes teams will select participants who meet inclusion criterion and the team will provide them with information leaflets. The information sheets will include contact details of the research team should any queries arise and contact details of somebody independent from the study. Parents/guardians of volunteers between 13-16 years old will also be able to access the information leaflet so they are aware of the study that their child has volunteered to participate in. The information leaflets will provide information surrounding consent. The information sheets will include a uniform resource locator (URL) where patients who have been selected by their diabetes teams will volunteer to download the app (SweetSpot) from.
Once the individual downloads the application or provided with an Android device by the University, they will be required to provide contact details for themselves, their GP and diabetes teams. This is so GP's can be made aware of the patients participation and so diabetes teams can be informed if the research team have concerns regarding an individual. Additionally, participants can be informed of any relevant developments throughout the study and this can be the forum to disseminate findings from the study.
All identifiable data will be stored electronically on a secure local server and password protected database. Any data removed from this database will be partially identifiable through a unique identifier (UID) which will link the two data sets. Analysis will be conducted on fully anonymised data.
Participants who have volunteered to take part in the study will have approximately four weeks to use the app and will be requested to attended an interview to provide feedback on the feasibility and user-friendliness of the app. As well as obtaining consent through the app, patients participating in this phase will provide consent to participate in the focus group.
Additionally, clinicians in the field will be aware of workshops for clinicians to interact with the app. This will be due to the chief investigator attending meetings explaining the study. A follow-up email will be disseminated to the teams with an information sheet and clinicians can volunteer to attend a workshop where they can use the app and provide feedback on the acceptability and feasibility of SweetSpot. Consent will be obtained at the workshop from clinicians.
The general format which each individual will follow contains 6 chapters with individual sessions which have been adapted from "ACT for diabetes self-management" manual. These include:
Chapter 1- Identifying problems.
- Information, consent demographics \& baseline questionnaires.
- Barriers to self-management, where barriers direct us.
- Responding to barriers.
Chapter 2 - A choice to be willing.
- Trying something different.
- Letting go of struggles.
Chapter 3-What's important to us.
- Noticing the direction we're moving.
- Choosing our direction.
Chapter 4- How to move towards what we care about.
- Moving towards our values.
- Barriers in moving towards our desired direction.
- Recognising our struggles.
Chapter 5 - How to work flexibly with obstacles.
- School.
- University.
- Work.
- Socialising.
- Family.
- Relationships.
Chapter 6-keeping going.
- How to keep on track.
- Choose what works.
Study Population:
Participants:
The study aims to recruit 12 participants from NHS Lothian, NHS Glasgow \& Clyde, NHS Fourth Valley, NHS Dumfries \& Galloway, NHS Borders, and NHS Lanarkshire.
Identifying Participants:
Clinician's from diabetes teams in the NHS boards involved will identify patients who meet inclusion criteria and competent to provide consent. These participants will be provided with information leaflets when they attend their regular NHS clinic appointment. A volunteer sample from those selected will pilot SweetSpot. Information leaflets will be available to parents/guardians of patients who are younger than 16 years old. An email address for the chief investigator and a person independent from the research team will also be included in the information leaflet.
Consent Process:
The information sheet containing the URL will state that if they download SweetSpot they are consenting to being involved in an interview to feedback their experience of using SweetSpot which will be recorded and used for research purposes. Participants will be asked to provide their email or phone number so the interview can be arranged, and for future contact should any additional information relevant to the research become available, they will be informed of this and so results can be disseminated via email. The chief investigator will introduce the study to Psychologists in the diabetes network and will visit diabetes teams who have shown an interest in the study to explain it in more detail to the whole team. Further to this an email will be disseminated to NHS diabetes clinicians regarding an educational workshop which introduces SweetSpot, allows clinicians to use SweetSpot and generates feedback from Clinicians regarding acceptability, feasibility and user-friendliness of the app. The workshop will have an information leaflet which will explain that by attending the workshop clinicians are consenting to being involved in a focus group to feedback their experience of using SweetSpot which will be recorded and used for research purposes and a subsequent consent form will be required to be completed at the workshops. It was deemed vital that formative work was conducted in collaboration with targeted users and service providers. Participants will be required to fill in a consent form before the workshops and focus groups. They are required to provide consent for two issues once they volunteer to download the app: 1. to consent to providing contact information of themselves, GP and diabetes team, 2. to consent to their data being used for research purposes. If they do not consent to both these issues they will not be able to access the app content.
There will be direct questions within the app which address consent:
- Do you consent to your diabetes team being informed of your participation in this study, and that further contact will be made if any concerns about your well-being arise?
- Do you consent to your data being used for research purposes in this study? If the participant responds no to question 1 or 2, then they will not be able to access the app. The GP and diabetes team will still be informed of their participation in the study. An information leaflet given to potential participants by their health care team will also cover consent issues.
A statement in the information sheets will also state:
By downloading the app you are consent that "I understand that relevant sections of my medical notes and data collected during the study may be looked at by individuals from the Sponsor (University of Edinburgh), from the NHS organisation or other authorities, where it is relevant to my taking part in this research. I give permission for these individuals to have access to my records."
Data Collection:
A unique identifier (UID) is assigned to each participant's data. All data will be stored electronically on an encrypted firewall protected secure local server and password protected database. The measures used to assess effectiveness of the application for self-monitoring behaviours are self-report of blood glucose measurements, insulin injecting, diet and physical exercise imputed daily. The outcome measures will be well-being, diabetes related distress and self-care behaviours.
Data Analysis for Qualitative Data:
The interviews and the workshop will be transcribed and the audio recording will be deleted. Framework analysis will be utilised for the workshop. Interpretive phenomenological analysis will be used for the interviews. This is because these types of analysis lies within the phenomenological school of thought, attempting to understand beliefs and attitudes about a topic. Therefore adopting a realist approach which assumes participants are reporting the truth in their experience. Within the realist framework an inductive approach is adopted to ensure interpretations were grounded in the data. It allows for themes to be generated through the research questions but also from the narratives provided by the participants. Framework analysis aims to report patterns within the data by using a systematic way to interpret information. The method uses a matrix which blends empirical investigation in creative study. Framework analysis has been found useful in analysing focus groups. Themes produced will identify amendments which need to be made for the intervention stage of the study. Interpretive phenomenological analysis is a useful analysis for individual interviews as it generates an in-depth analysis of a person's experience.
Data Analysis for Quantitative Data:
A simple t-test analysis will be conducted if the data is normally distributed, or Wilcoxon-sign if the data is non-normally distributed.
- Conditions
- Type 1 Diabetes
- Being tested
- Acceptance and Commitment Therapy
- Medical subject headings
- Diabetes Mellitus, Type 1
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Acceptance and Commitment TherapyBehavioural
An application based on Acceptance and Commitment Therapy
| Study group | Role | What they receive |
|---|---|---|
| SweetSpot users | Other | Participants will interact with the smartphone application for as long or as little as they wish. They will be asked to complete questionnaires at baseline (pre), 4 weeks (post), and to attend an interview. Receives: Behavioral: Acceptance and Commitment Therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Acceptability and feasibility of using SweetSpot
Interviews will be conducted
Measured: 4 weeks
Secondary outcomes (5)
Change in Psychological Flexibility - Diabetes specific (DAAS)
The Diabetes Acceptance and Action Scale (DAAS), is a 42 item measure which measures diabetes acceptance aimed at adolescents with type 1 diabetes (Greco \& Hart, 2005). It is scored on a five point likert scale from never true to always true, with approximately half the items being reverse scored. This scale has been revised to form a 14 item version which has been found to have good overall reliability α = 0.796, good reliability for action subscale α =0 .71, and good reliability for avoidance subscale α = 0.78.
Measured: baseline, 4 weeks
Change in Psychological Flexibility (AFQ-Y8)
The Avoidance and Fusion Questionnaire for youths 8 item measure (AFQ-Y8) will be utilised for the generic questionnaire. The AFQ-Y8 (Greco et al., 2008) is an 8 item measure which is measures psychological inflexibility in adolescents. It is scored using a five point likert scale from not at all true to very true. The measure is found to have good reliability α = 0.83.
Measured: baseline, 4 weeks
Change in Diabetes Related Distress (PAID-T)
It has been advised to incorporate the WHO-5 with the Problem Areas in Diabetes (PAID) specific measure (Snoek, 2006). Diabetes related emotional distress will be measured by The Problem Areas in Diabetes-Teen Version (PAID-T). The PAID-T is a 26 item measure scored on a likert scale from one-to-six ascertaining how certain situations have distressed individuals over the past month, showing good reliability α = 0.96 (Weissberg-Benchell \& Antisdel-Lomaglio, 2011).
Measured: baseline, 4 weeks
Change in Glucose Management
Participants will be asked to input daily glucose measurements. The average will be calculated at the 4 time points to determine whether there has been an improvement in glucose management
Measured: baseline, 4 weeks
Well-being
The well-being 5 item measure
Measured: baseline, 4 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Aug 2015 (estimated)
- Study startMay 2015
- Primary completionApr 2016
- Study completionApr 2016
Why it stopped: No uptake from potential participants
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Type 1 DiabetesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 17 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Edinburgh
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Estelle Barker, University of Edinburgh
- Investigators
- Estelle L Barker, MSc, Principal investigator, University of Edinburgh
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02526069
- Sponsor's protocol ID
- 15-SS-0064
- Acronym
- ACT
- Status last verified
- May 2016
- First submitted
- 13 Aug 2015
- Last updated
- 12 May 2016
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 May 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An ACT Based Application for Young People With Type 1 Diabetes
- ClinicalTrials.gov ID
- NCT02526069
- Acronym / sponsor ID
- ACT / 15-SS-0064
- Conditions
- Type 1 Diabetes
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: No uptake from potential participants
- Enrolment
- 17 participants (actual)
- Lead sponsor
- University of EdinburghUniversity, hospital or other
- Study start
- May 2015
- Primary completion
- Apr 2016 (actual)
- Study completion
- Apr 2016 (actual)
- First posted
- 18 Aug 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Study Objectives:
This study aims to assess the feasibility and acceptability of an application utilising Acceptance and Commitment Therapy in young people with type 1 diabetes.
Primary Research Questions:
Is an ACT based application feasible and acceptable to young people with type 1 diabetes.
Study Design:
Patients will use the app for four weeks and then be invited to attend an interview discussing the acceptability, usability and feasibility of the app. Clinician's will also be invited to take part in a workshop where they interact with the app and provide feedback.
Consent for will be obtained through the app. Additional consent for the recording of interviews will be obtained in paper format and stored in a secure locked cabinet at Edinburgh University.
Quantitative data will also be collected on well-being, psychological flexibility, and data usage.
Data Collection
Qualitative feedback:
Interviews will be recorded and transcribed using unique identifiers.
Outcome measures and data usage patterns:
Data will be collected on a password protected database which can only be obtained via a password protected and encrypted server from University of Edinburgh.
Data Analysis:
Phase 1:
Framework analysis and interpretive phenomenological analysis will be utilised to create themes from the qualitative feedback.
Detailed description
Study Design:
The diabetes teams will select participants who meet inclusion criterion and the team will provide them with information leaflets. The information sheets will include contact details of the research team should any queries arise and contact details of somebody independent from the study. Parents/guardians of volunteers between 13-16 years old will also be able to access the information leaflet so they are aware of the study that their child has volunteered to participate in. The information leaflets will provide information surrounding consent. The information sheets will include a uniform resource locator (URL) where patients who have been selected by their diabetes teams will volunteer to download the app (SweetSpot) from.
Once the individual downloads the application or provided with an Android device by the University, they will be required to provide contact details for themselves, their GP and diabetes teams. This is so GP's can be made aware of the patients participation and so diabetes teams can be informed if the research team have concerns regarding an individual. Additionally, participants can be informed of any relevant developments throughout the study and this can be the forum to disseminate findings from the study.
All identifiable data will be stored electronically on a secure local server and password protected database. Any data removed from this database will be partially identifiable through a unique identifier (UID) which will link the two data sets. Analysis will be conducted on fully anonymised data.
Participants who have volunteered to take part in the study will have approximately four weeks to use the app and will be requested to attended an interview to provide feedback on the feasibility and user-friendliness of the app. As well as obtaining consent through the app, patients participating in this phase will provide consent to participate in the focus group.
Additionally, clinicians in the field will be aware of workshops for clinicians to interact with the app. This will be due to the chief investigator attending meetings explaining the study. A follow-up email will be disseminated to the teams with an information sheet and clinicians can volunteer to attend a workshop where they can use the app and provide feedback on the acceptability and feasibility of SweetSpot. Consent will be obtained at the workshop from clinicians.
The general format which each individual will follow contains 6 chapters with individual sessions which have been adapted from "ACT for diabetes self-management" manual. These include:
Chapter 1- Identifying problems.
- Information, consent demographics \& baseline questionnaires.
- Barriers to self-management, where barriers direct us.
- Responding to barriers.
Chapter 2 - A choice to be willing.
- Trying something different.
- Letting go of struggles.
Chapter 3-What's important to us.
- Noticing the direction we're moving.
- Choosing our direction.
Chapter 4- How to move towards what we care about.
- Moving towards our values.
- Barriers in moving towards our desired direction.
- Recognising our struggles.
Chapter 5 - How to work flexibly with obstacles.
- School.
- University.
- Work.
- Socialising.
- Family.
- Relationships.
Chapter 6-keeping going.
- How to keep on track.
- Choose what works.
Study Population:
Participants:
The study aims to recruit 12 participants from NHS Lothian, NHS Glasgow \& Clyde, NHS Fourth Valley, NHS Dumfries \& Galloway, NHS Borders, and NHS Lanarkshire.
Identifying Participants:
Clinician's from diabetes teams in the NHS boards involved will identify patients who meet inclusion criteria and competent to provide consent. These participants will be provided with information leaflets when they attend their regular NHS clinic appointment. A volunteer sample from those selected will pilot SweetSpot. Information leaflets will be available to parents/guardians of patients who are younger than 16 years old. An email address for the chief investigator and a person independent from the research team will also be included in the information leaflet.
Consent Process:
The information sheet containing the URL will state that if they download SweetSpot they are consenting to being involved in an interview to feedback their experience of using SweetSpot which will be recorded and used for research purposes. Participants will be asked to provide their email or phone number so the interview can be arranged, and for future contact should any additional information relevant to the research become available, they will be informed of this and so results can be disseminated via email. The chief investigator will introduce the study to Psychologists in the diabetes network and will visit diabetes teams who have shown an interest in the study to explain it in more detail to the whole team. Further to this an email will be disseminated to NHS diabetes clinicians regarding an educational workshop which introduces SweetSpot, allows clinicians to use SweetSpot and generates feedback from Clinicians regarding acceptability, feasibility and user-friendliness of the app. The workshop will have an information leaflet which will explain that by attending the workshop clinicians are consenting to being involved in a focus group to feedback their experience of using SweetSpot which will be recorded and used for research purposes and a subsequent consent form will be required to be completed at the workshops. It was deemed vital that formative work was conducted in collaboration with targeted users and service providers. Participants will be required to fill in a consent form before the workshops and focus groups. They are required to provide consent for two issues once they volunteer to download the app: 1. to consent to providing contact information of themselves, GP and diabetes team, 2. to consent to their data being used for research purposes. If they do not consent to both these issues they will not be able to access the app content.
There will be direct questions within the app which address consent:
- Do you consent to your diabetes team being informed of your participation in this study, and that further contact will be made if any concerns about your well-being arise?
- Do you consent to your data being used for research purposes in this study? If the participant responds no to question 1 or 2, then they will not be able to access the app. The GP and diabetes team will still be informed of their participation in the study. An information leaflet given to potential participants by their health care team will also cover consent issues.
A statement in the information sheets will also state:
By downloading the app you are consent that "I understand that relevant sections of my medical notes and data collected during the study may be looked at by individuals from the Sponsor (University of Edinburgh), from the NHS organisation or other authorities, where it is relevant to my taking part in this research. I give permission for these individuals to have access to my records."
Data Collection:
A unique identifier (UID) is assigned to each participant's data. All data will be stored electronically on an encrypted firewall protected secure local server and password protected database. The measures used to assess effectiveness of the application for self-monitoring behaviours are self-report of blood glucose measurements, insulin injecting, diet and physical exercise imputed daily. The outcome measures will be well-being, diabetes related distress and self-care behaviours.
Data Analysis for Qualitative Data:
The interviews and the workshop will be transcribed and the audio recording will be deleted. Framework analysis will be utilised for the workshop. Interpretive phenomenological analysis will be used for the interviews. This is because these types of analysis lies within the phenomenological school of thought, attempting to understand beliefs and attitudes about a topic. Therefore adopting a realist approach which assumes participants are reporting the truth in their experience. Within the realist framework an inductive approach is adopted to ensure interpretations were grounded in the data. It allows for themes to be generated through the research questions but also from the narratives provided by the participants. Framework analysis aims to report patterns within the data by using a systematic way to interpret information. The method uses a matrix which blends empirical investigation in creative study. Framework analysis has been found useful in analysing focus groups. Themes produced will identify amendments which need to be made for the intervention stage of the study. Interpretive phenomenological analysis is a useful analysis for individual interviews as it generates an in-depth analysis of a person's experience.
Data Analysis for Quantitative Data:
A simple t-test analysis will be conducted if the data is normally distributed, or Wilcoxon-sign if the data is non-normally distributed.
Study design
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| SweetSpot users | Other | Behavioral: Acceptance and Commitment TherapyParticipants will interact with the smartphone application for as long or as little as they wish. They will be asked to complete questionnaires at baseline (pre), 4 weeks (post), and to attend an interview. |
Who may qualify
- Ages
- 13 to 22 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult
Key inclusion criteria (5 listed)
- 13-22 year olds diagnosed with type 1 diabetes or a clinician working in this field
- Understand English
- Android phone
- If a patient to have been diagnosed for at least 6 months
- Ability to give consent
Key exclusion criteria (1 listed)
- Young people experiencing significant mental health issues. This includes those who are suicidal, experiencing psychosis, or are severely depressed. This will be assessed by the diabetes team which includes psychologists and those potential participants which meet this exclusion criteria will not be asked to participate in the study by the diabetes or research team.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Acceptance and Commitment TherapyAn application based on Acceptance and Commitment Therapy | Behavioural | SweetSpot users |
Primary outcome
Acceptability and feasibility of using SweetSpot
Time frame: 4 weeks
Interviews will be conducted
5 secondary outcomes
Change in Psychological Flexibility - Diabetes specific (DAAS)
Time frame: baseline, 4 weeks
Change in Psychological Flexibility (AFQ-Y8)
Time frame: baseline, 4 weeks
Change in Diabetes Related Distress (PAID-T)
Time frame: baseline, 4 weeks
Change in Glucose Management
Time frame: baseline, 4 weeks
Well-being
Time frame: baseline, 4 weeks
Results and safety
The study was stopped early (reason given: No uptake from potential participants). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 May 2016.
Related trials for Type 1 Diabetes
Active, not recruitingPhase 3
Clinical Application of Stem Cell Educator Therapy in Type 1 Diabetes
Type 1 Diabetes
RecruitingObservational study
Study of High Density Lipoprotein Function in Type 1 Diabetic Patients With Nephropathy
Type 1 Diabetes
Active, not recruitingPhase 1/2
A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus
Obesity
RecruitingPhase 3
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
Obesity or Overweight
Not yet recruitingPhase 1/2
Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas
Sarcoma, Osteoid Sarcoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Estelle L Barker, MSc principal investigator
University of Edinburgh
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Acceptance and Commitment Therapy in people with Type 1 Diabetes, run by University of Edinburgh at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 12 May 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: No uptake from potential participants). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Acceptability and feasibility of using SweetSpot (time frame: 4 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 May 2016.